Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google Scholar 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella Macário Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella Macário Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Prof. R. StephanieHuang – Oncology and Precision Medicine – Best Researcher Award 

Posted on by Pencis

Prof. R. StephanieHuang - Oncology and Precision Medicine - Best Researcher Award 

University Of Minnesota - Minneapolis, MN - United States

Author Profile

Scopus 

Orcid

Early Academic Pursuits

Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.

Professional Endeavors

Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.

Contributions and Research Focus on Oncology and Precision Medicine

Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.

Impact and Influence

As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.

Academic Citations

Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.

Legacy and Future Contributions

Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.

Notable Publications

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.

A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.

 

 

 

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Posted on by Pencis

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Dr. Michele Moreau – Oncology Therapeutics and Novel Approaches –  Best Researcher Award

Posted on by Pencis

Dr. Michele Moreau - Oncology Therapeutics and Novel Approaches -  Best Researcher Award

Johns Hopkins University - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Michele Moreau's academic journey began with a Bachelor of Science (B.S.) in Physics from the University of Kentucky in May 2009. Following this foundational degree, Michele pursued a Master of Science (M.S.) in Applied Physics from the Physics Department at the University of Massachusetts Boston, graduating in May 2012. Building upon this, Michele achieved another M.S. in Medical Physics from the Radiological Sciences Department at the University of Massachusetts Lowell in May 2022. These early academic pursuits set the stage for Michele's specialization in the field of biomedical engineering and biotechnology.

PROFESSIONAL ENDEAVORS

During Michele Moreau's academic journey, she served as a Teaching and Research Assistant at the University of Massachusetts Lowell from 2014 to 2023. Her role involved teaching an Introductory Physics Lab course and grading lab reports and quizzes. Furthermore, Michele completed a 6-month internship focused on developing a platform for catalyzing collaborative global Cancer Care Education and Research (CaRE). This initiative aimed to enhance Access to Medical Physics Education and Research Excellence (AMPERE), showcasing her commitment to global health initiatives.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPEUTICS AND NOVEL APPROACHES

Michele Moreau's primary research focus revolves around biomedical research in cancer therapy. As a Graduate Research Trainee from 2015 to 2023 at prestigious institutions such as Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Johns Hopkins School of Medicine, Michele specialized in engineering solid and liquid formulations of smart radiotherapy biomaterials. Her expertise encompasses a wide range of techniques and methodologies, including:Engineering Smart Radiotherapy Biomaterials,Monolayer and 3D Cell Culture etc.,

IMPACT AND INFLUENCE

Michele Moreau's research contributions have the potential to revolutionize cancer therapy by improving the effectiveness of in-situ treatment of tumor masses. Her work on smart radiotherapy biomaterials and associated techniques could significantly enhance the precision and efficiency of cancer treatments, benefiting countless patients worldwide.

ACADEMIC CITES

Michele's research findings and contributions to the field of biomedical engineering and biotechnology have likely been cited in various academic publications, journals, and conferences. Her collaborations with esteemed institutions and her focus on cutting-edge research topics make her a notable figure in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Michele Moreau is expected to be conferred with a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell in August 2023, her legacy in the field is already taking shape. Her multidisciplinary approach to cancer therapy, combining physics, engineering, and biology, paves the way for future advancements in the field. Michele's dedication to improving cancer treatments and her commitment to global health initiatives highlight her potential to leave a lasting impact on biomedical research and patient care.

NOTABLE PUBLICATIONS

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment. 2024

Pre-Clinical Investigations of the Pharmacodynamics of Immunogenic Smart Radiotherapy Biomaterials (iSRB). 2023

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination. 2023

Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment. 2023

Phytoradiotherapy to enhance cancer treatment outcomes with cannabidiol, bitter melon juice, and plant hemoglobin. 2023

 

 

Ms Menekse Turna – Radiation Oncology – Best Researcher Award

Posted on by Pencis

Ms Menekse Turna - Radiation Oncology - Best Researcher Award

Anadolu Medical Center - Turkey

AUTHOR PROFILE

Orchid

Scopus

Early Academic Pursuits

Menekşe Turna began her academic journey with a strong foundation at the Karadeniz Technical University Faculty Of Medicine in Trabzon, Turkey, where she dedicated six years of study from 2005 to 2011. This period laid the groundwork for her future contributions in the field of medicine.

Professional Endeavors

Upon completing her medical education, Menekşe Turna delved into the specialized field of Radiation Oncology. She started her professional journey at Okmeydani Research and Training Hospital in Istanbul, where she gained valuable experience from 2012 to 2016. Later, she expanded her horizons by joining the St James Institute of Oncology in Leeds, England, as a Clinical Observer in 2015-2016, further enriching her knowledge in the international medical landscape.

Contributions and Research Focus on Radiation oncology

Menekşe Turna's primary focus in Radiation Oncology showcases her commitment to advancing cancer treatment. Her contributions to the field involve a keen interest in therapeutic radiology, emphasizing precision and efficacy in cancer treatment methods. Through her work, she aims to contribute to the ongoing advancements in radiation therapy for improved patient outcomes.

Academic Cites

Menekşe Turna's academic achievements are reflected in her successful completion of the Second degree in the Board Exam of the Turkish Society for Radiation Oncology in 2016. This recognition signifies her expertise and proficiency in the field.

Legacy and Future Contributions

As a dedicated medical professional, Menekşe Turna is already leaving a positive mark on the field of Radiation Oncology. Her legacy lies in the lives she impacts through precise and compassionate cancer care. Looking forward, she envisions continued contributions to research, education, and patient care, leaving an enduring legacy in the medical community.

NOTABLE PUBLICATIONS

Stereotactic radiosurgery in brain metastasis: treatment outcomes and patterns of failure.2023

Evaluation of clinically involved lymph nodes with deformable registration in breast cancer radiotherapy.2022

Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients.2021

 

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali – Targeted Cancer Therapy – Best Researcher Award

Posted on by Pencis

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali - Targeted Cancer Therapy - Best Researcher Award

SRTA city - Egypt

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Marwa Muhammad Abu-Serie Ali initiated her academic journey in the field of biochemistry, obtaining a Bachelor's degree from Alexandria University, Egypt, with honors. She continued her academic pursuits with a Master's degree in Biochemistry from the same university in 2008. Later, in 2014, Marwa achieved a significant milestone by completing her Ph.D. in the Biochemistry Department at the Faculty of Science, Alexandria University, Egypt. Her doctoral thesis focused on a model for drug assessment of colon cancer induced in murine cells.

PROFESSIONAL ENDEAVORS:

Marwa's professional journey encompasses various roles, starting from a Delegated Demonstrator at Alexandria University to her current position as an Associate Professor in the Medical Biotechnology Department at the Genetic Engineering and Biotechnology Research Institute (GEBRI) in Egypt. She has consistently contributed to research and academia, progressing from Assistant Researcher to Researcher and eventually to her current leadership position as an Associate Professor.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Marwa's research focus is on medical biotechnology, with specific interests in tageted cancer therapy studies. Her work includes projects such as the assessment of nanotherapeutic approaches in colon cancer, the development of anti-coronavirus agents, and the evaluation of novel anticancer agents. She has also explored the anti-tumor efficacy of various formulations against different types of carcinoma, emphasizing a comprehensive and innovative approach to cancer treatment.

IMPACT AND INFLUENCE:

Marwa has made significant contributions to the scientific community through her involvement in research projects funded by prestigious organizations like the Science & Technology Development Fund (STDF), Fulbright, and the Academy of Scientific Research and Technology Center (STC). Her work has not only expanded scientific knowledge but has also paved the way for potential breakthroughs in cancer treatment and the fight against infectious diseases.

ACADEMIC CITATIONS:

Marwa's academic work has likely garnered citations in various research publications, reflecting the impact of her contributions to the field of medical biotechnology. These citations signify the acknowledgment and recognition of her research by peers and fellow scientists.

LEGACY AND FUTURE CONTRIBUTIONS:

Marwa's legacy lies in her commitment to advancing knowledge in medical biotechnology, particularly in cancer research and antiviral drug development. Her future contributions are anticipated to further shape the landscape of biomedical research, potentially leading to breakthroughs in cancer treatment and viral therapeutics.

NOTABLE PUBLICATIONS

Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.2023

Inhibitory effect of lactoferrin-coated zinc nanoparticles on SARS-CoV-2 replication and entry along with improvement of lung fibrosis induced in adult male albino rats.2023

Concurrent Tissue Engineering for Wound Healing in Diabetic Rats Utilizing Dual Actions of Green Synthesized CuO NPs Prepared from Two Plants Grown in Egypt.2023

 

Mr.Christopher Olowosoke – Targeted Cancer Therapy – Best Researcher Award

Posted on by Pencis

Mr.Christopher Olowosoke - Targeted Cancer Therapy - Best Researcher Award

Federal University of Technology Akure - Nigeria

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Christopher Busayo Olowosoke embarked on his academic journey with a focus on biotechnology. His dedication to academic excellence was evident during his West African Senior School Certificate Examination at Isefun Community Senior Secondary School, Lagos State, Nigeria, where he achieved a grade of Distinction in the Science stream. This early success set the stage for his future pursuits in the field of biotechnology and information technology.

PROFESSIONAL ENDEAVORS

With a passion for biotechnology and an interest in the chemistry of natural products and pharmacology, Christopher pursued his first degree at the Federal University of Technology, Akure, Ondo State, Nigeria. Graduating with an outstanding grade of 4.73/5.00 in Biotechnology in 2020, he showcased his commitment to academic excellence. His undergraduate thesis, "Identification of pungency-associated genes in some indigenous Nigerian hot pepper varieties," demonstrated his engagement with cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

As a Student Research Assistant at the Federal University of Technology, Akure, Christopher actively contributed to research in the Departments of Biochemistry, Biotechnology, and Microbiology from 2017 to 2021. His involvement in in vivo, in vitro, and in silico procedures for diabetes and  targeted cancer therapy underscored his commitment to addressing metabolic and cellular proliferation dysregulation, aligning with Sustainable Development Goal 3 (SDG 3). Additionally, his work on the phyto-treatment of diabetes using Andrographic paniculata showcased his dedication to innovative therapeutic approaches.

IMPACT AND INFLUENCE

Christopher's impact extended beyond the laboratory. As a Laboratory Research Assistant at Chrisland University Biotechnology Department from 2022 to the present, he played a pivotal role in organizing practical sessions and providing training in bioinformatics and molecular biology for undergraduates. His leadership as the Founder of B.Khrease Academic Consult since 2018 highlights his commitment to facilitating student projects, mentorship, and collaboration with academic experts.

ACADEMIC CITES

Christopher's research contributions are recognized through his publications. His paper titled "Multiregulator of EZH2-PPARs Therapeutic Targets" was published in Applied Biochemistry and Biotechnology in 2023. This publication addresses critical aspects of pancreatic insulin production and cancer dysregulation. The link to his full publication list on ResearchGate (https://www.researchgate.net/profile/Christopher-Olowosoke/research) reflects his ongoing scholarly pursuits.

LEGACY AND FUTURE CONTRIBUTIONS

Christopher's legacy includes leadership roles, such as being the Founder of B.Khrease Academic Consult and serving as the Promotional and Development Committee Head at the Institute of Bioinformatics and Molecular Therapeutic (IBMT) since 2021. His active participation in conferences, workshops, and professional webinars, as well as affiliations with prestigious societies, showcases his commitment to staying at the forefront of biotechnological advancements.

AWARDS/GRANT

Christopher's achievements are acknowledged through various awards and grants, including being a beneficiary of the American Society for Nutrition Early Career Professional Mentoring Program in 2023 and securing the second position in the Peeref International Best Poster Presentation in the same year. His involvement in securing the TETFUND Grant Award for the Biotechnology Department in 2022 and the UNESCO-ICB Scholarship in 2020 further demonstrates his capacity to contribute significantly to his field.

NOTABLE PUBLICATION

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.

Biomedical Advancements in Cancer

Posted on by Pencis

Biomedical Advancements in Cancer

 

Introduction: In recent years, the field of biomedical advancements in cancer research has witnessed remarkable breakthroughs that have transformed our understanding of the disease and revolutionized treatment options. These advancements offer new hope to patients and hold the promise of improved outcomes in the fight against cancer.

Subtopics in Biomedical Advancements in Cancer:

Immunotherapy and Immune Checkpoint Inhibitors: Immune checkpoint inhibitors have emerged as a game-changer in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. CAR-T cell therapy, PD-1 inhibitors, and CTLA-4 inhibitors are some of the key developments in this area.

Precision Medicine and Genomic Profiling: Advancements in genomic sequencing technologies have paved the way for precision medicine in cancer treatment. Tailoring therapies based on the genetic makeup of a patient’s tumor has improved treatment efficacy and reduced side effects.

Liquid Biopsies for Early Detection: Liquid biopsies involve the non-invasive analysis of blood or other bodily fluids to detect cancer-related genetic mutations and biomarkers. These tests offer early detection capabilities and real-time monitoring of cancer progression.

Targeted Therapies and Personalized Cancer Drugs: Targeted therapies are designed to specifically inhibit the molecular pathways driving cancer growth. Advances in drug development have led to a wide range of targeted treatments, enhancing the effectiveness of cancer therapy while minimizing collateral damage to healthy cells.

AI and Machine Learning in Cancer Diagnosis and Treatment: Artificial intelligence and machine learning algorithms are being employed to analyze vast datasets of medical information, aiding in early cancer diagnosis, treatment planning, and predicting patient outcomes. These technologies have the potential to optimize cancer care and streamline research efforts.

These subtopics represent just a fraction of the exciting developments in the biomedical field related to cancer research. Continued research and innovation in these areas are bringing us closer to more effective treatments, early detection methods, and improved patient outcomes in the battle against cancer.